ACI: 15th Summit on Biosimilars & Innovator Biologics
June 21, 2024
O’Melveny partner Hassen Sayeed will be a speaker at this year’s ACI Summit on Biosimilars and Innovator Biologics, which offers practical insights and strategies for tackling legal, regulatory, and commercialization issues for the industry. Sayeed will join a panel discussion which will take a look at key Federal and District Court lawsuits impacting BPCIA evolving development.
Topics include:
- Diving Deep into Regeneron’s BPCIA litigation against Celltrion, Samsung Bioepis, Formycon, and Mylan for each of their proposed biosimilars of EYLEA; Exploring Regeneron’s motion to establish multi-district litigation encompassing the aflibercept BPCIA cases
- Learning the latest biologic patent litigation strategies: Timing the lawsuit and seeking preliminary injunctions to block accused infringer’s at risk launch
- Learning the latest biosimilar patent litigation strategies: Appreciating when and how courts find permanent injunctions appropriate before receiving FDA approval; and analyzing the decision to argue against a PI versus not launching at the end of the market exclusivity period
ACI: 15th Summit on Biosimilars & Innovator Biologics
June 20 – 21, 2024
New York City Bar Association, NY
Reviewing Cases and Distilling Trends: The Key Federal and District Court Lawsuits Shaping the BPCIA Landscape
June 21, 2024
8:15 am ET
Learn more and register here.